Novel Circulating Biomarkers in Aortic Valve Stenosis

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Pathophysiology

Background:

• The pathophysiology and progression factors of aortic stenosis are not fully understood.
• Biomarkers, beyond B-type natriuretic peptide (BNP), are being investigated for their role in aortic stenosis.

Purpose of the Study:

• To review current knowledge on aortic stenosis biomarkers.
• To highlight emerging biomarkers and their potential clinical applications.
• To provide a roadmap for translating biomarker insights into clinical practice.

Main Methods:

• Literature review of existing and emerging biomarkers for aortic stenosis.
• Analysis of biomarker associations with disease progression and pathophysiology.

Main Results:

• Lipoprotein(a) [Lp(a)] is identified as a promising biomarker for risk stratification in aortic stenosis.
• Elevated Lp(a) levels correlate with accelerated aortic stenosis progression, linked to valve calcification.
• Other biomarkers like matrix metalloproteinases, monocytes, and metabolites show potential but require further investigation.

Conclusions:

• Lipoprotein(a) [Lp(a)] offers significant potential for risk stratification in aortic stenosis.
• Further research is crucial to elucidate the mechanisms of action for emerging biomarkers in aortic stenosis.